Tags

Type your tag names separated by a space and hit enter

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
Int J Infect Dis. 2007 Nov; 11 Suppl 2:S29-35.IJ

Abstract

OBJECTIVE

To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST).

METHODS

Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring > or =14 days after the third dose of vaccine for up to 2 years.

RESULTS

In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions.

CONCLUSIONS

PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort.

Authors+Show Affiliations

University of Tampere Medical School, Tampere, Finland. timo.vesikari@uta.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18162243

Citation

Vesikari, Timo, et al. "Efficacy of a Pentavalent Rotavirus Vaccine in Reducing Rotavirus-associated Health Care Utilization Across Three Regions (11 Countries)." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 11 Suppl 2, 2007, pp. S29-35.
Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11 Suppl 2:S29-35.
Vesikari, T., Itzler, R., Matson, D. O., Santosham, M., Christie, C. D., Coia, M., Cook, J. R., Koch, G., & Heaton, P. (2007). Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 11 Suppl 2, S29-35. https://doi.org/10.1016/S1201-9712(07)60019-8
Vesikari T, et al. Efficacy of a Pentavalent Rotavirus Vaccine in Reducing Rotavirus-associated Health Care Utilization Across Three Regions (11 Countries). Int J Infect Dis. 2007;11 Suppl 2:S29-35. PubMed PMID: 18162243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). AU - Vesikari,Timo, AU - Itzler,Robbin, AU - Matson,David O, AU - Santosham,Mathuram, AU - Christie,Celia D C, AU - Coia,Michele, AU - Cook,John R, AU - Koch,Gary, AU - Heaton,Penny, PY - 2008/3/8/pubmed PY - 2008/3/28/medline PY - 2008/3/8/entrez SP - S29 EP - 35 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 11 Suppl 2 N2 - OBJECTIVE: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST). METHODS: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring > or =14 days after the third dose of vaccine for up to 2 years. RESULTS: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions. CONCLUSIONS: PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort. SN - 1201-9712 UR - https://www.unboundmedicine.com/medline/citation/18162243/Efficacy_of_a_pentavalent_rotavirus_vaccine_in_reducing_rotavirus_associated_health_care_utilization_across_three_regions__11_countries__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(07)60019-8 DB - PRIME DP - Unbound Medicine ER -